These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 29961690)

  • 1. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
    Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
    J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?
    Elhaj M; Charles J; Pedroza C; Liu X; Zhou X; Estrada-Y-Martin RM; Gonzalez EB; Lewis DE; Draeger HT; Kim S; Arnett FC; Mayes MD; Assassi S
    J Rheumatol; 2013 Jul; 40(7):1114-20. PubMed ID: 23588945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
    Kuwana M; Shirai Y; Takeuchi T
    J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
    Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
    Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease.
    Watanabe S; Kase K; Saeki K; Ohkura N; Murata A; Waseda Y; Takato H; Ichikawa Y; Yasui M; Kasahara K
    Respir Med; 2022 Jan; 191():106689. PubMed ID: 34844174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
    Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
    Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
    Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
    Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
    Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts.
    Wu M; Baron M; Pedroza C; Salazar GA; Ying J; Charles J; Agarwal SK; Hudson M; Pope J; Zhou X; Reveille JD; Fritzler MJ; Mayes MD; Assassi S
    Arthritis Rheumatol; 2017 Sep; 69(9):1871-1878. PubMed ID: 28575534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
    Hant FN; Ludwicka-Bradley A; Wang HJ; Li N; Elashoff R; Tashkin DP; Silver RM;
    J Rheumatol; 2009 Apr; 36(4):773-80. PubMed ID: 19286849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
    Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
    Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
    J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
    De Lauretis A; Sestini P; Pantelidis P; Hoyles R; Hansell DM; Goh NS; Zappala CJ; Visca D; Maher TM; Denton CP; Ong VH; Abraham DJ; Kelleher P; Hector L; Wells AU; Renzoni EA
    J Rheumatol; 2013 Apr; 40(4):435-46. PubMed ID: 23378460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
    Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
    Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
    Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
    Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease.
    Nawata T; Shirai Y; Suzuki M; Kuwana M
    Rheumatology (Oxford); 2021 Jan; 60(1):250-255. PubMed ID: 32699895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.
    Assassi S; Sharif R; Lasky RE; McNearney TA; Estrada-Y-Martin RM; Draeger H; Nair DK; Fritzler MJ; Reveille JD; Arnett FC; Mayes MD;
    Arthritis Res Ther; 2010; 12(5):R166. PubMed ID: 20813056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?
    Liu X; Mayes MD; Pedroza C; Draeger HT; Gonzalez EB; Harper BE; Reveille JD; Assassi S
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1375-80. PubMed ID: 23401350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.